What does Monte Rosa Therapeutics, Inc. do?
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs),…
What is Monte Rosa Therapeutics, Inc.'s P/E and P/B ratio?
Monte Rosa Therapeutics, Inc. has a P/E ratio of -6.3 and a P/B ratio of 1.95.
What is Monte Rosa Therapeutics, Inc.'s debt-to-equity ratio?
Monte Rosa Therapeutics, Inc. has a debt-to-equity ratio of 0.08.
How much does Monte Rosa Therapeutics, Inc. owe compared with what it owns?
Monte Rosa Therapeutics, Inc. owes $0.29 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Monte Rosa Therapeutics, Inc.'s Positivity rank?
Monte Rosa Therapeutics, Inc. is ranked #3,160 of 6,774 companies globally and #1,262 of 4,000 in United States on PositoAI, with a Positivity Score of 20,810.
Does Monte Rosa Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Monte Rosa Therapeutics, Inc..
Where can I read the latest news about Monte Rosa Therapeutics, Inc.?
Recent headlines about Monte Rosa Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Monte Rosa Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Monte Rosa Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.